LLY - Eli Lilly and Company
| Previous Close | 86.36 |
| Open | 86.52 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 86.33 - 87.38 |
| 52 Week Range | 64.18 - 89.09 |
| Volume | 3,223,192 |
| Avg. Volume | 3,599,481 |
| Market Cap | 91.34B |
| Beta | 0.15 |
| PE Ratio (TTM) | 37.75 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.08 (2.41%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
Associated Press•20 hours agoGovernor says change-resistant Indiana should think globally
Factory work dwindled as companies moved operations overseas. Indiana, a manufacturing powerhouse where you once could get a good-paying job even without a high school education, was falling behind. Yet ...
- Benzinga•2 days ago
Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday
The earnings parade continues with Caterpillar Inc. (NYSE: CAT ) and Eli Lilly & Co (NYSE: LLY ) scheduled to report early next week. Both companies are expected to release results before market open on ...
- Forbes•2 days ago
Earnings Preview: Caterpillar And Eli Lilly Report on Tuesday
Heavy-equipment maker Caterpillar and pharma company Eli Lilly & Co. report earnings before the open on Tues., Oct. 24. Here’s a look at what might be expected.
- Bloomberg•2 days ago
China Biotech Promise Struggles to Keep Foreign Innovators
As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back.
- Reuters•3 days ago
Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug
WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is effective, reasonably safe and should be approved by the FDA. The panel voted 16-0 with one abstention in favor of the drug being approved.
- Zacks•4 days ago
What to Expect from Big Pharmas After J&J's Solid Q3 Results?
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
- Market Realist•4 days ago
Behind Eli Lilly’s Performance in 3Q17
LLY stock rose ~4.5% in 3Q17 and has risen 17.7% YTD (year-to-date) as of October 16.
- Market Realist•4 days ago
Understanding Eli Lilly’s Position in Neurology Drugs after 1H17
In 1H17, Eli Lilly's (LLY) Cymbalta reported revenues of around $381.2 million, compared with $435.2 million in 1H16.
- Market Realist•4 days ago
Inside Eli Lilly’s Endocrinology Franchise Positioned after 1H17
In 1H17, Eli Lilly’s (LLY) Humalog reported revenues of around $1.39 million, compared with $1.31 million in 1H16.
- Motley Fool•4 days ago
10 Stunning Numbers You Need to Know About Breast Cancer
There's more good news than you might think.
Markit•4 days agoSee what the IHS Markit Score report has to say about Eli Lilly And Co.
Eli Lilly And Co NYSE:LLY
- Zacks•4 days ago
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
- Market Realist•4 days ago
Why Eli Lilly’s Basaglar, Jardiance, and Trajenta Could Witness Steady Growth in 2018
In 1H17, Eli Lilly's (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.
- Reuters•4 days ago
Eli Lilly to collaborate with Germany's CureVac on cancer vaccines
U.S. drugmaker Eli Lilly and Co said on Wednesday it will collaborate with CureVac AG on development of up to five immunotherapy cancer vaccines using the German company's messenger RNA (mRNA) technology. Under terms of the deal, CureVac will receive $50 million up front and Lilly will take an equity stake in CureVac worth about $53 million (45 million euros).
- Reuters•4 days ago
Trump favors ex-pharma executive Azar for health secretary -Politico
U.S. President Donald Trump is leaning toward naming former pharmaceutical industry executive Alex Azar as his pick to lead the Department of Health and Human Services, Politico reported on Tuesday, citing ...
- Market Realist•5 days ago
How Eli Lilly’s Taltz Is Positioned after 1H17
In 1H17, Eli Lilly’s (LLY) Taltz reported revenues of ~$235.3 million, compared with $19.3 million in 1H16.
- Forbes•6 days ago
The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
- Market Realist•6 days ago
This Could Be Eli Lilly’s Long-Term Growth Driver
In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines.
- Market Realist•6 days ago
Inside Eli Lilly’s Oncology Portfolio: Key Updates
In 1H17, Eli Lilly’s (LLY) Alimta reported revenues of around $1.0 billion, compared with $1.2 billion in 1H16.
- Market Realist•6 days ago
Gauging Eli Lilly’s Position with Cyramza after 1H17
In 1H17, Eli Lilly’s (LLY) Cyramza reported revenues of around $357.5 million, compared with $278.0 million in 1H16.
- Zacks•9 days ago
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
The pharma/biotech sector has a number of things going in its favor.
- Market Realist•9 days ago
This Could Boost Eli Lilly’s Revenue Growth in 2018
In September, the FDA approved Eli Lilly's (LLY) Verzenio-fulvestrant combination therapy for the treatment of women with hormone receptor-positive or HR+.
- Market Realist•9 days ago
How Eli Lilly Is Positioned after 1H17
In 1H17, Eli Lilly (LLY) generated revenues of around $11.0 billion, compared with $10.3 billion in 1H16.
- Bloomberg Video•3 days ago
Ken Langone on Black Monday Crash, Regulatory Landscape
Oct.19 -- Ken Langone, chairman at Invemed Associates and co-founder at Home Depot, recounts his experience during the Black Monday market crash in 1987 and the future of financial regulation. He speaks with Bloomberg's Jason Kelly from the Robin Hood Investors Conference on "Bloomberg Markets."
- CNBC Videos•4 days ago
This hot trade is about to get even hotter: Trader
The “Fast Money” traders discuss the health care sector seeing a pop and where it could go from here.
